These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12699015)

  • 1. Challenges in delivering antiretroviral treatment in resource poor countries.
    Hosseinipour MC; Kazembe PN; Sanne IM; van der Horst CM
    AIDS; 2002; 16 Suppl 4():S177-87. PubMed ID: 12699015
    [No Abstract]   [Full Text] [Related]  

  • 2. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges.
    Katabira ET; Oelrichs RB
    AIDS; 2007 Jul; 21 Suppl 4():S5-10. PubMed ID: 17620753
    [No Abstract]   [Full Text] [Related]  

  • 3. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 4. 'DOTS' and 'DOT' for delivering antiretroviral therapy in resource-poor countries.
    Harries AD
    AIDS; 2004 Mar; 18(5):830-1; author reply 831-2. PubMed ID: 15075526
    [No Abstract]   [Full Text] [Related]  

  • 5. Highly active antiretroviral therapy (HAART)--plus: next steps to enhance HAART in resource-limited areas?
    Flanigan TP; Wools-Kaloustain K; Harwell J; Cu-Uvin S; Kimaiyo S; Carter EJ
    Clin Infect Dis; 2007 Dec; 45(11):1499-501. PubMed ID: 17990234
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
    Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
    AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.
    Colebunders R; Moses KR; Laurence J; Shihab HM; Semitala F; Lutwama F; Bakeera-Kitaka S; Lynen L; Spacek L; Reynolds SJ; Quinn TC; Viner B; Mayanja-Kizza H
    Lancet Infect Dis; 2006 Jan; 6(1):53-9. PubMed ID: 16377535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human resource aspects of antiretroviral treatment delivery models: current practices and recommendations.
    Assefa Y; Van Damme W; Hermann K
    Curr Opin HIV AIDS; 2010 Jan; 5(1):78-82. PubMed ID: 20046151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world?
    Lawn SD; Myer L; Wood R
    Clin Infect Dis; 2005 Dec; 41(11):1683-4; author reply 1684. PubMed ID: 16267745
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral treatment in resource-poor settings: clinical research priorities.
    Rabkin M; El-Sadr W; Katzenstein DA; Mukherjee J; Masur H; Mugyenyi P; Munderi P; Darbyshire J
    Lancet; 2002 Nov; 360(9344):1503-5. PubMed ID: 12433534
    [No Abstract]   [Full Text] [Related]  

  • 11. Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care.
    Bemelmans M; van den Akker T; Ford N; Philips M; Zachariah R; Harries A; Schouten E; Hermann K; Mwagomba B; Massaquoi M
    Trop Med Int Health; 2010 Dec; 15(12):1413-20. PubMed ID: 20958897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scale-up of HIV care and treatment: can it transform healthcare services in resource-limited settings?
    El-Sadr WM; Abrams EJ
    AIDS; 2007 Oct; 21 Suppl 5():S65-70. PubMed ID: 18090271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A record 6.6 million patients in poor countries received antiretroviral treatment in 2010.
    Zarocostas J
    BMJ; 2011 Jun; 342():d3555. PubMed ID: 21646311
    [No Abstract]   [Full Text] [Related]  

  • 14. Three million HIV/AIDS sufferers could receive anti-retroviral therapy by 2005: new hope for those in developing world.
    Lepr Rev; 2002 Sep; 73(3):295-6. PubMed ID: 12449898
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiretroviral treatment in developing countries.
    Nachega J
    Hopkins HIV Rep; 2002 Sep; 14(5):10-1, 15. PubMed ID: 12240641
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV-1 care in resource-poor settings: a view from Haiti.
    Mukherjee JS
    Lancet; 2003 Sep; 362(9388):994-5. PubMed ID: 14513853
    [No Abstract]   [Full Text] [Related]  

  • 17. Involving behavioral scientists, health care providers, and HIV-infected patients as collaborators in theory-based HIV prevention and antiretroviral adherence interventions.
    Fisher JD; Cornman DH; Norton WE; Fisher WA
    J Acquir Immune Defic Syndr; 2006 Dec; 43 Suppl 1():S10-7. PubMed ID: 17133191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV medication adherence: from Haitian DOT to generics in Brazil.
    Jones SG
    Fla Nurse; 2002 Sep; 50(3):28. PubMed ID: 12387104
    [No Abstract]   [Full Text] [Related]  

  • 19. Accrued HIV evidence turns treatment dogma on its head.
    Check E
    Nature; 2003 Aug; 424(6951):866. PubMed ID: 12931150
    [No Abstract]   [Full Text] [Related]  

  • 20. Access to adequate nutrition is a major potential obstacle to antiretroviral adherence among HIV-infected individuals in Rwanda.
    Au JT; Kayitenkore K; Shutes E; Karita E; Peters PJ; Tichacek A; Allen SA
    AIDS; 2006 Oct; 20(16):2116-8. PubMed ID: 17053359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.